Bio-Techne Corp. (TECH)

Total return at 5 years: -12.5%/year = -13.0% appreciation + 0.6% dividend. The target price ($36) is ex-dividend; the $2 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $37 · Multiples $30) is below the market price ($72).

Today — expensive, no margin of safety: at $72 trades ~139.1% above its value discounted to today (~$30); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$19.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($72) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The price discounts growth (19.9%/year) above our base case (3.5%/year) → it is priced for a demanding scenario and leaves little cushion against a slowdown.

That growth implies ~$0.5 bn of owner earnings in year 5 (vs ~$0.3 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). Cash accumulates the retained surplus —what is not returned as dividend or buyback—, so that EV falls and multiples compress going forward. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

The year-model values Bio-Techne as a single operating business (Protein Sciences and Diagnostics and Spatial Biology share the same life-science reagents/instruments economics) by EV/NOPAT, within the medical-technology band [16-22×]. Year 0 is the TTM closed on June 30, 2026 (10-K filed August 24, 2026, XBRL up to date — no rebasing needed). Revenue starts from the actual reported trajectory (FY24 +2%, FY25 +5.2%, FY26 -0.4%, consolidated organic 0%) rather than company guidance, which the company does not publish numerically: the August 12, 2026 earnings 8-K carries no guidance and the pending merger with Merck KGaA restricts forward-looking communications. The base case starts at +2.0% in year 1 (close to the three-year average) and gently accelerates to +5.0% by year 5, reflecting the growing mix toward Diagnostics and Spatial Biology (organic +4-6% over the last two fiscal years) against the contraction in Protein Sciences (-1% organic from pricing pressure). The operating margin starts from the 20.7% TTM — normalized, without the non-economic $84.2M impairment that depressed FY2025 — and expands modestly toward 22.4% by year 5. Stock-based compensation (3.4% of revenue, 15.7% of FCF) is already expensed in the operating income that underpins the metric, so no further adjustment is needed. Cash accumulates (accumulateCash) because the company retains ~65% of free cash flow and has been repaying debt; the market price, however, currently reflects the arbitrage on the pending merger with Merck KGaA ($73.00/share), not this standalone valuation.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (EV falls as cash increases). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $36 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $72, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $36 in 5 years plus $2 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $30. Against the current market price ($72), the margin of safety is -139.1% (trades above the maximum → a premium is paid) and the total return at that price would be -12.5% annually.

• Price vs. merger. The market price ($72.44) trades at just a ~0.8% discount to the agreed merger price ($73.00), reflecting high probability of closing.
• Implied entry multiple. The merger price implies a multiple well above the medical-technology band [16-22×], consistent with an acquisition premium rather than a going-concern valuation.
• Standalone value at 5 years. At a medical-technology multiple on projected NOPAT, the business's intrinsic value comes in well below the current market price.
• Non-closing risk. If the merger does not close, the stock would retreat toward that standalone value, well below current trading levels.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✕ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (116%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Cash generation. OCF of $292M on revenue of $1,215M (24% margin) and low capex (2.4% of revenue); healthy cash conversion.
• Return on capital. 9.3% on real invested capital (equity + debt − cash), just below the 10% bar.
• Stock-based compensation. SBC equals 3.4% of revenue and 15.7% of FCF — material, but already expensed in the operating income that underpins this valuation (EV/NOPAT).
• Earnings quality. The FY2025 earnings drop ($73.4M) was almost entirely a non-economic impairment of $84.2M on assets held for sale; FY2026 normalizes to $182M.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

The two reportable segments show different trajectories: Protein Sciences grew from FY2024 to FY2026 but with the most recent fiscal year essentially flat and negative organic volume (-1%) from pricing pressure. Diagnostics and Spatial Biology declined in level in FY2026 despite +4% organic growth, because the Exosome Diagnostics divestiture (classified held-for-sale) subtracted ~8 points from the reported figure. The difference between the reported level and the organic growth disclosed by the company is key to reading these rows without confusing portfolio changes with underlying demand.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Recent trajectory. FY24 +2%, FY25 +5.2%, FY26 -0.4% reported (0% organic) — a noisy trajectory from FX, divestiture and pricing pressure, not a clean trend.
• Fastest-growing segment. Diagnostics and Spatial Biology grew +4% (FY26) and +6% (FY25) organic, driven by the Comet/RNAscope spatial platform.
• Contracting segment. Protein Sciences (72% of revenue) fell -1% organic in FY26 from unfavorable product mix and pricing pressure.
• Company guidance. No numerical projection published: the earnings 8-K and the 10-K do not include guidance, and the pending merger restricts forward-looking communications.

• Revenue recurrence. Consumable reagents with repeat purchase in established research protocols; the mix shift toward regulated diagnostics adds further stability.
• Product differentiation. A broad portfolio under recognized brands, but with no demonstrated pricing power: Protein Sciences organic volume fell -1% from pricing pressure.
• Geographic diversification. ~48% of sales outside the U.S., with manufacturing in North America, the U.K., Canada, Switzerland and China.
• Customer concentration. No customer exceeded 10% of sales in any segment over the last three fiscal years.
• Demand cyclicality. Depends on academic and pharmaceutical research spending, sensitive to government budgets and pharma mergers.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0.1 bn
• ✓Interest coverage (EBIT / interest)26.2x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 116% of ROIC
• ✕Value creation (ROIC − 10% bar)-1pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.3x — no over-investment
• !Float / working capitalConsumes cash $0 bn (positive WC)
• !Dilution (SBC % of revenue + shares)SBC 3.4% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Net cash position. Cash of $265M against gross debt of $200M — a positive net cash position of ~$65M.
• Leverage. Gross debt equals less than 1× TTM NOPAT; no visible refinancing pressure.
• Debt repayment. The company repaid $146M of long-term debt in FY2026, reducing the balance from $346M to $200M.
• Merger-related restrictions. The agreement with Merck KGaA restricts operating outside the ordinary course and declaring dividends beyond the prior policy while pending.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Alignment. No founding or controlling shareholders; relevant ownership is 100% passive institutional (Vanguard, BlackRock, T. Rowe Price).
• Capital allocation. 65% of flow retained (debt repayment and cash) in FY2026, with buybacks down 85% year over year and no new M&A in the fiscal year.
• Recent strategic decision. The board unanimously approved the sale to Merck KGaA at $73.00/share in cash, crystallizing shareholder value through an ongoing transaction.
• Continuity. CEO in the role since February 2024 after eight years at the company; the merger, if it closes, changes leadership entirely.

• The market price ($72.44) is anchored to the merger agreement with Merck KGaA ($73.00/share in cash), not to a fundamental read of the business: the ~0.8% spread reflects the estimated time to closing and residual regulatory and vote risk, typical of a merger arbitrage.
• There is no evidence of missing buyers or motivated sellers in the traditional sense of the method: the quote does not express a discrepancy between perception and business reality, but the probability-weighted likelihood that the transaction closes on the agreed terms.
• Against the standalone going-concern value (medical-technology multiple on NOPAT), the current price comes in well above: this filing's verdict is not a signal that the market is overvaluing the business, but the reflection of an ongoing corporate transaction.

Bio-Techne does not fit the usual taxonomy of missing buyers or motivated sellers because its price today is not set by the business: it is set by the merger agreement with Merck KGaA at $73.00/share, signed on June 25, 2026 and awaiting the September 23 shareholder vote. The market price ($72.44) trades at an arbitrage spread of ~0.8% over the agreed price, consistent with a transaction that has already obtained approval from the German Bundeskartellamt and remains in process in other jurisdictions. Comparing that price against this filing's standalone intrinsic value — built with the medical-technology multiple on projected NOPAT, without adjusting for the control premium — produces a large gap, but that gap is not an opportunity or a market error: it is the difference between what the business is worth as a going concern and what a strategic buyer is willing to pay to acquire it whole. If the deal falls through, the price should retreat toward standalone value; if it closes, the shareholder captures the remaining spread.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -17%/year (-62% total): the margin of safety protects the downside. The bull (-8%/year, -34% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Merger non-closing. The agreement requires shareholder approval (vote on Sep-23-2026) and regulatory approval; the German Bundeskartellamt has already approved, but other jurisdictions remain in process. The termination fee is ~$230.5M.
• Pricing pressure. Protein Sciences (72% of revenue) faces competition from low-cost entrants and customer consolidation that pressures margins.
• Dependence on research funding. Spending by academic, pharmaceutical and government customers is cyclical and depends on budgets outside the company's control.
• M&A risk. The growth strategy depends on acquisitions (Lunaphore, Wilson Wolf, Spear Bio); goodwill (38% of total assets) is exposed to impairment if performance does not keep pace.
• Arbitrage price. With the price already close to the merger value, the room for further upside is limited and the risk is asymmetric to the downside if the deal falls through.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: ROIC 9% does not clear the 10% bar.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 4% at a multiple/growth of 17.0 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 2% (EBIT/EV) + ROIC 9% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts 20% vs our 4%: priced for perfection, no favorable mispricing.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -18%/yr over 5y (material loss) → risk of permanent capital loss.

• Pat Dorsey Moat strength (Five Rules)

  A narrow moat, stable; sources: intangibles, switching costs, efficient scale → partially passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  The price demands 20% growth, far above our 4% — heroic assumptions.